Erdafitinib 3 mg, 4 mg, 5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 3 mg, 4 mg, 5 mg

Reference Brands: Balversa (USA)

Category: Oncology Cancer Care

Erdafitinib is an oral FGFR inhibitor for advanced urothelial (bladder) cancer with susceptible FGFR3 genetic changes. It is made by Janssen and sold as Balversa in 3 mg, 4 mg and 5 mg tablets, and is still under patent with no approved generic. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Erdafitinib is an oral pan-FGFR tyrosine kinase inhibitor, active against fibroblast growth factor receptors 1 through 4. Its approved use is in locally advanced or metastatic urothelial carcinoma carrying susceptible FGFR2 or FGFR3 alterations, in patients who have progressed on prior therapy. It is a genuinely biomarker-gated drug: eligibility depends on a companion diagnostic identifying the alteration, and without that testing infrastructure the product cannot be used.

The toxicity profile follows directly from the target. Hyperphosphataemia is on-target rather than idiosyncratic — FGF23 signalling governs renal phosphate handling — and serum phosphate is used to titrate the dose upward rather than simply as a safety check. Serous retinopathy and central serous chorioretinopathy require ophthalmic monitoring, and nail, skin and oral mucosal toxicity are common enough to affect adherence.

Sourcing notes. Originator product, on patent, with no generic route. Treat enquiries as innovator supply or named-patient import rather than contract manufacturing. Market access depends on FGFR companion diagnostics being available in the destination country — a buyer without that testing pathway cannot use the product at any price.